These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26313327)

  • 1. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Expert Opin Drug Saf; 2015 Oct; 14(10):1495-506. PubMed ID: 26313327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
    Wang Z; Zhang J; Zhang L; Liu P; Xie Y; Zhou Q
    J Chemother; 2016 Aug; 28(4):328-34. PubMed ID: 26099278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents.
    Abdel-Rahman O; ElHalawani H
    Crit Rev Oncol Hematol; 2016 Jun; 102():89-100. PubMed ID: 27129437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis.
    Abdel-Rahman O; ElHalawani H
    Chemotherapy; 2014; 60(5-6):325-33. PubMed ID: 26302785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
    Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis.
    Tian R; Yan H; Zhang F; Sun P; Zheng X; Zhu Y; Wang Q; He J
    Oncotarget; 2016 Oct; 7(40):66182-66191. PubMed ID: 27507055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
    Abdel-Rahman O; ElHalawani H; Essam-Eldin S
    Expert Opin Drug Saf; 2016 Jan; 15(1):5-20. PubMed ID: 26513339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Future Oncol; 2015; 11(21):2949-61. PubMed ID: 26422782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1229-42. PubMed ID: 25119858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
    Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
    Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Curr Med Res Opin; 2015 May; 31(5):975-86. PubMed ID: 25708852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015; 15(7):847-58. PubMed ID: 25994247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
    Hapani S; Chu D; Wu S
    Lancet Oncol; 2009 Jun; 10(6):559-68. PubMed ID: 19482548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis.
    Qi WX; Shen F; Qing Z; Xiao-Mao G
    Tumour Biol; 2014 Nov; 35(11):10715-22. PubMed ID: 25070487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1529-36. PubMed ID: 25159115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials.
    Wang K; Qu X; Wang Y; Dong W; Shen H; Zhang T; Ni Y; Liu Q; Du J
    Clin Drug Investig; 2016 Jan; 36(1):27-39. PubMed ID: 26547200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Opin Drug Saf; 2014 Aug; 13(8):999-1008. PubMed ID: 24930544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials.
    Xiao B; Wang W; Zhang D
    Onco Targets Ther; 2018; 11():5059-5074. PubMed ID: 30174444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):465-75. PubMed ID: 25664933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.